Valuation: Evotec SE

Market Cap 62Cr 71Cr 57Cr 53Cr 99Cr 6.83TCr 101.28Cr 683.5Cr 267.89Cr 3.34TCr 266.04Cr 260.22Cr 12TCr P/E 2026 *
-4.02x
P/E 2027 * -10x
Enterprise Value 66Cr 76Cr 61Cr 56Cr 106.16Cr 7.29TCr 108.07Cr 729.3Cr 285.84Cr 3.56TCr 283.87Cr 277.66Cr 12TCr EV / Sales 2026 *
1.1x
EV / Sales 2027 * 0.98x
Free-Float
89.91%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 55 01/07/2024
Director of Finance/CFO - 01/05/2026
Chief Operating Officer - 01/05/2026
Director TitleAgeSince
Director/Board Member 58 19/06/2019
Director/Board Member 64 01/06/2021
Director/Board Member 43 22/06/2022
Change 5-day change 1-year change 3-year change Capi.($)
+1.30%-.--% - - 71Cr
-1.07%+0.38%+2.06%+5.66% 5.03TCr
-2.85%-5.58%+373.90%+572.09% 3.92TCr
+1.78%+3.29%+33.49%-4.80% 3.45TCr
+1.98%+5.15%+17.69%+61.68% 3.46TCr
+0.06%-0.57%+3.35%+27.42% 2.7TCr
-3.27%-6.27% - - 1.67TCr
+1.64%+1.11%+72.02%+121.18% 1.51TCr
+0.29%+3.64%+15.30%+17.80% 1.39TCr
-1.21%+2.74%+16.77%-30.96% 1.32TCr
Average +0.14%+0.81%+66.82%+96.26% 2.72TCr
Weighted average by Cap. +0.13%+0.70%+79.63%+118.91%

Financials

2026 *2027 *
Net sales 60Cr 69Cr 55Cr 51Cr 96Cr 6.61TCr 98Cr 661.85Cr 259.4Cr 3.24TCr 257.62Cr 251.98Cr 11TCr 74Cr 84Cr 68Cr 63Cr 118.27Cr 8.12TCr 120.39Cr 812.46Cr 318.43Cr 3.97TCr 316.24Cr 309.32Cr 14TCr
Net income -15Cr -17Cr -14Cr -12Cr -24Cr -1.62TCr -24Cr -162.43Cr -64Cr -793.94Cr -63Cr -62Cr -2.73TCr -4.75Cr -5.43Cr -4.39Cr -4.03Cr -7.62Cr -523.2Cr -7.76Cr -52Cr -21Cr -256.01Cr -20Cr -20Cr -881.69Cr
Net Debt 4.15Cr 4.75Cr 3.84Cr 3.52Cr 6.67Cr 457.54Cr 6.79Cr 46Cr 18Cr 223.89Cr 18Cr 17Cr 771.05Cr 11Cr 12Cr 9.73Cr 8.93Cr 17Cr 1.16TCr 17Cr 116.07Cr 45Cr 567.36Cr 45Cr 44Cr 1.95TCr
Logo Evotec SE
Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
-